𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma

✍ Scribed by Karen G. Louie; Thomas C. Hamilton; Brent C. Behrens; Karen R. Grotzinger; Wilma M. McKoy; Charles E. Myers; Robert C. Young; Robert F. Ozols

Publisher
Springer
Year
1986
Tongue
English
Weight
455 KB
Volume
18
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Preclinical evaluation of DISC-GMCSF for
Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma
✍ Peter T. Loudon; Cornelia S. McLean; Gilly Martin; Jayne Curry; M. Leigh Shaw; C πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 142 KB

## Abstract ## Background DISC‐hGMCSF is a gH‐deleted HSV‐2 based vector expressing human GM‐CSF that has entered clinical trials for the therapy of metastatic melanoma. To determine whether this product also has potential to treat breast carcinoma, a series of __in vitro__ and __in vivo__ studies

Preclinical and clinical evaluation of p
Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer
✍ Julian Adams πŸ“‚ Article πŸ“… 2002 πŸ› Elsevier Science 🌐 English βš– 824 KB

The proteasome is a multicatalytic protease, present in all eukaryotic cells, that is primarily responsible for intracellular protein degradation. By destroying regulatory proteins or their inhibitors, the proteasome influences many cellular regulatory signals and is thus a potential target for phar